SHS Capital

Type

Venture Capital

Status

Active

Location

Tubingen, Germany

Total investments

39

Average round size

6M

Portfolio companies

29

Rounds per year

1.30

Lead investments

12

Follow on index

0.26

Exits

2

Stages of investment
Private EquityLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsManufacturingMedical DeviceMedicalPersonal HealthPharmaceuticalTherapeuticsEmergency Medicine

Summary

SHS Gesellschaft fur Beteiligungsmanagement appeared to be the VC, which was created in 1993. The main department of described VC is located in the Tu00fcbingen. The venture was found in Europe in Germany.

This organization was formed by Bernhard Schirmers, Reinhilde Spatscheck.

Deals in the range of 5 - 10 millions dollars are the general things for fund. Opposing the other organizations, this SHS Gesellschaft fur Beteiligungsmanagement works on 25 percentage points less the average amount of lead investments. The high activity for fund was in 2015. The fund is constantly included in less than 2 investment rounds annually. The real fund results show that this VC is 22 percentage points more often commits exit comparing to other companies.

The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the SHS Gesellschaft fur Beteiligungsmanagement, startups are often financed by KfW, Earlybird Venture Capital, Delta Partners. The meaningful sponsors for the fund in investment in the same round are KfW, Unternehmertum Venture Capital Partners, Earlybird Venture Capital. In the next rounds fund is usually obtained by KfW, Bayern Kapital GmbH, Earlybird Venture Capital.

Among the most popular portfolio startups of the fund, we may highlight Miracor Medical, AOT - Advanced Osteotomy Tools, numares HEALTH. The fund has exact preference in a number of founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Medical, Biotechnology. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Germany. Besides, a startup needs to be aged 6-10 years to get the investment from the fund.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesMedtechHealthcare
Stage focus
Series CSeries DSeries FSeries E
Geo focus
AlbaniaAustriaBelgiumBosnia and HerzegovinaBulgaria Show 37 more
Check size
11M — 54M

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
EUR 270000000
Fund raised date
2023-07-26

Analytics

Total investments
39
Lead investments
12
Exits
2
Rounds per year
1.30
Follow on index
0.26
Investments by industry
  • Health Care (23)
  • Medical Device (19)
  • Medical (16)
  • Biotechnology (10)
  • Health Diagnostics (10)
  • Show 29 more
Investments by region
  • Germany (16)
  • Belgium (4)
  • France (3)
  • Netherlands (1)
  • Switzerland (7)
  • Show 5 more
Peak activity year
2015

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
13
Group Appearance index
0.67
Avg. company exit year
10

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
GNA Biosolutions 06 Aug 2019 Biotechnology, Health Care, Health Diagnostics, Medical Late Stage Venture 13M Munich, Bavaria, Germany
Simulands 02 Mar 2023 Health Care, Medical Device Seed 11M Zürich, Switzerland, Zurich

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.